Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia
Study Details
Study Description
Brief Summary
-
Goal: This study is a randomized phase II interventional study. The purpose of this study is to see if addition of oral rifaximin tablets during allogeneic stem cell transplant can improve the quality of gut microbiome and reduce chances of death, infections and graft versus host disease (GVHD) post-transplant.
-
The study objectives are as follows:
-
Primary Objective: To determine the impact of rifaximin on gut microbial diversity and compare it with controls.
-
Secondary Objectives: a. To determine non-relapse mortality at 1-year post transplant in patients who receive peri-transplant transplant rifaximin and compare it with controls.
-
- To compare the incidence of severe GVHD in patients who receive peri-transplant rifaximin with the controls.
-
- To determine impact of gut decontamination with rifaximin on incidence of MDR sepsis and usage of higher antibiotics (e.g. Carbapenems, colistin, tigecycline, ceftazidime avibactum and ceftriaxone-sulbactam EDTA) in first 6 months post BMT.
-
- To determine the impact of rifaximin induced gut manipulation on immune reconstitution, T cell repertoire post-transplant and cytokine profile.
-
Exploratory objective: To use single cell transcriptomics (SCT) to identify immune cell profile in gut biopsies post allogeneic stem cell transplant whenever biopsy is done, to correlate the impact of microbiome on gut immunity.
-
Intervention: Tab Rifaximin 200 mg will be given orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care post-transplant treatment.
-
Comparator Agent: Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
The gut microbiome plays a significant role in modulating the immune re-constitution post allogeneic stem cell transplant (ASCT). Low gut microbial diversity has been consistently associated with poor outcomes of transplant including increased incidence of acute graft versus host disease (aGVHD), post-transplant bacterial sepsis and non-relapse mortality (NRM). However, the exact mechanism by which gut microbiome influences local as well as systemic immunity is not completely known, and is thought to be due to the impact of microbial metabolites on intestinal epithelial cells and host antigen-presenting cells. Understanding these mechanisms and modulating the microbiome may be crucial to improving transplant outcomes. Rifaximin is a locally acting antibiotic that has been approved for manipulating the gut microbiome in hepatic failure. It is unique because of its ability to clear pathogenic bacteria, while preserving the anaerobic commensals. It can potentially modify the gut microbiome to increase the alpha diversity and this may help reduce aGVHD, infectious complications, and mortality post-transplant. High incidence of multidrug resistant sepsis and frequent use of broad spectrum antibiotics in India, would result in higher rates of dysbiotic gut- making microbiome manipulation to improve transplant outcomes more relevant in our country. We are proposing a randomized controlled trial to understand the benefits of modulating the gut microbiome in patients of ASCT while investigating the local and global immune repertoire using single cell sequencing and multicolour flow cytometry.
Study design: Single center, open-labeled, phase II study, randomized controlled trial.
Primary Objective: To determine the impact of rifaximin on gut microbial alpha diversity and compare it with controls.
Secondary Objectives:
To determine impact of rifaximin on 1 year non relapse mortality post-transplant, incidence of grade III/IV aGVHD, incidence of MDR sepsis, patterns of immune cell reconstitution, and cytokine profile post-transplant.
Exploratory objective: To use single-cell transcriptomics (SCT) to identify immune cell profiles in gut biopsies post ASCT in order to get insights into the impact of the microbiome on local gut immunity.
Study population: Adult patients who undergo ASCT at the Tata Memorial Centre.
Study Methodology in brief: Patients would be randomized to receive either oral tablet rifaximin 200 mg twice daily along with standard posttransplant treatment or to receive standard of care treatment alone. Stool samples and blood samples will be collected at different time points for microbiome analysis and immune cell profiling respectively. We plan to perform 16s rRNA-based next-generation sequencing of all variable regions using a phased primer approach using stool DNA as a template. Gut microbiome diversity will be calculated using the inverse Simpson index. Immune cell profile would be analyzed using 16 color flow cytometry. In selected cases where patients undergo colonoscopic gut biopsy for aGVHD, we will also obtain samples for transcriptome sequencing. This will help us understand how immune cells interact with gut mucosa and microbiome in patients of aGVHD
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Tab Rifaximin with Allogeneic stem cell transplant Tab Rifaximin 200 mg will be given orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care post transplant treatment |
Drug: Rifaximin with allogeneic stem cell transplant
Tab Rifaximin 200 mg will begiven orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care posttransplant treatment
|
| Active Comparator: Allogeneic stem cell transplant Allogeneic stem cell transplant: Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed. |
Procedure: Allogeneic stem cell transplant
Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.
|
Outcome Measures
Primary Outcome Measures
- Impact of rifaximin on gut microbial diversity. [15 days post transplant]
To determine the impact of rifaximin on gut microbial diversity as measured by inverse simpson index (ISI) and compare it with controls.
Secondary Outcome Measures
- Non relapse mortality [1 year post transplant]
To determine non relapse mortality (NRM) at 1 year post transplant in patients who receive peri transplant transplant rifaximin and compare it with controls
- Incidence of severe (grade III/IV) acute graft versus host disease [1 year post transplant]
To compare the incidence of severe (grade III/IV) acute graft versus host disease (aGVHD) in patients who receive peri-transplant rifaximin with that in control arm.
- Impact of gut decontamination with rifaximin on incidence of multidrug resistant sepsis post transplant. [6 months post transplant]
To determine impact of gut decontamination with rifaximin on incidence of multidrug resistant (MDR) sepsis and usage of higher antibiotics (e.g. Carbapenems, colistin, tigecycline, ceftazidime avibactum and ceftriaxone-sulbactam EDTA) in first 6 months post BMT
- Impact of rifaximin induced gut manipulation on immune reconstitution [1 year post transplant]
To determine the impact of rifaximin induced gut manipulation on immune reconstitution, T cell repertoire post transplant
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with acute leukemia and planned for aHSCT.
-
Patients with age more than 18 years (> 18 years).
-
Patients who give written informed consent.
-
Underlying hematologic malignancy in which aHSCT is indicated.
-
ECOG performance status 0, 1 or 2 (on day of enrolment).
-
Adequate Liver function test with serum SGOT/AST and SGPT/ALT < 3.0 times upper normal limit (ULN) and total bilirubin < 2.0 times ULN (on day of enrolment).
Exclusion Criteria:
- Known hypersensitivity to rifaximin or other rifampicin antimicrobial agents b. Patients on therapy with antibiotics for bacterial or fungal infections on day of enrolment (Except for azole prophylaxis for fungal infections, acyclovir prophylaxis for herpes and cotrimoxazole prophylaxis for pneumocystis jerovecii infections, which are permissible). c. Patients with current or past history of inflammatory bowel disease d. Patients with history of major bowel resection or patients with colostomy. e. Use of rifampicin or rifaximin in last 1 month before enrolment. f. Any serious medical condition or psychiatric illness that would prevent the subject from signing the informed consent form or in opinion of the investigator make the patient unfit for enrolment in the trial. g. Patients on the following P-glycoprotein inhibitors at time of enrolment: Verapamil, ketoconazole and itraconazole will be excluded from the study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Tata Memorial Centre
Investigators
- Principal Investigator: Dr. Anant Gokarn, Gokarn, Advanced Centre for Treatment, Research and Education in Cancer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 900872